Dr. John Cush RheumNow
5 years 4 months ago
Cohort study of 4.4 million adolescents w/ 7.6 million fluoroquinolone Rxs found a 90 day LOW risk of tendon ruptures (0.47/1000 Pt yrs) or tendinitis (9.34 per 1000 person-years). These events were rare in kids and appear to be more common in adults. https://t.co/52uGZKAptc
Dr. John Cush RheumNow
5 years 4 months ago
DASH study: ?effect of diet on BP in 459 adults given 1) USA diet; 2) Fiber, fruits, Veggie (FFV) or 3) DASH diet. Compared to typical American diet, DASH diet (less so FFV) reduced mean SUA 0.25 mg/dl (P=.004); moreso w/ higher SUA levels https://t.co/XhCK9xp67P
Dr. John Cush RheumNow
5 years 4 months ago
BSRBR: Demyelinating Disease Following Anti-TNFα Therapy
Analysis of patients receiving TNFi therapy in the BSRBR shows that the risk of demyelination is rare but is marginally increased by taking TNFi therapy.
https://t.co/oHJXOa96Kn https://t.co/m2GpeEQxnP
Anifrolumab has been studied in two large phase 3 trials in systemic lupus erythematosus (SLE) patients; pooled data from both the TULIP-1 and TULIP-2 trials were used to show that anifrolumab reduces flares in patients with moderate to severe SLE.
Anifrolumab is a human monoclonal antibody to type I interferon receptor subunit and is being developed to treat active SLE patients.
Dr. John Cush RheumNow
5 years 4 months ago
RheumNow Live 2021 is now available for everyone!
RNL 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Night Rheumatology (TNR).
We hope to see you there!
https://t.co/jaisVc2kGt https://t.co/vYHm8QGD14
Dr. John Cush RheumNow
5 years 4 months ago
Genomic study of 1190 vasculitis pts & 11302 controls identfied a genetic variant, rs3743841, located in an intron of the NAGPA gene, reached genome-wide significance for Kawasaki (p= 8.06x10−10) and IgA vasculitis.(p= 1.25x10−7; OR 1.47 ) https://t.co/bUX5MdmOSM
Tildrakizumab, a monoclonal antibody targeting interleukin-23p19 studied in adults with psoriatic arthritis (PsA), was found to be superior to placebo and well tolerated without reports of uveitis, systemic fungal infections, inflammatory bowel disease, major cardiac events or death.
Dr. John Cush RheumNow
5 years 4 months ago
Today Sandoz announced that the US Supreme Court has denied Sandoz appeal for their Enbrel biosimilar (Erelzi; which is FDA approved) to be marketed in the US. This biosimilar is available out side of the US, but wont be US available till 2029. https://t.co/aABw1dpbMr
Dr. John Cush RheumNow
5 years 4 months ago
"Arthritis Mutilans" - worse outcome to chronic inflammatory arthritis is due to 5 disorders:
1) RA
2) Psoriatic arthritis
3) Tophaceous gout
4) polyarticular JIA
5) Multicentric reticulohistiocytosis (Ive never seen this!!)
https://t.co/XYmBEW1F0R https://t.co/tGWNG9Aklw
Dr. John Cush RheumNow
5 years 4 months ago
Dr. Janet Pope - Comorbidities in SLE
From ACR 2019
https://t.co/1BjfVOfL4i
#LupusAwarenessMonth https://t.co/apjrwa36dA
Dr. John Cush RheumNow
5 years 4 months ago
Increased Methotrexate Liver Disease in Psoriasis
https://t.co/sEZajDIkSz
Dr. John Cush RheumNow
5 years 4 months ago
RNL 2021 - Assessing Psoriasis: Melodie Young, MSN, ANP-c
https://t.co/ZzOnJOtKjz
Dr. John Cush RheumNow
5 years 4 months ago
Join us this Tuesday for Tuesday Night Rheumatology focusing on Spondyloarthritis with sessions from Dr. Nigil Haroon, Dr. Artie Kavanaugh, and Dr. Robert Wang.
https://t.co/Jr6H0Yg6xs https://t.co/UXx37liLSZ
Dr. John Cush RheumNow
5 years 4 months ago
RNL 2021 - Spondyloarthritis Q & A Panel Discussion
https://t.co/3oFZNV0XI6
